News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
Explainers
ASX cancer stocks guide: Here’s everything you need to know
News
CLOSING BELL: Local markets dragged lower by central bank angst; lithium minnows and New Hope offer some hope
Health & Biotech
ASX Health Stocks: Lumos granted US FDA emergency-use approval for virus test kit, ViraDx
News
Top 10 at 10: Orexplore lands big fish, inking $1.55m commercial agreement with BHP
Health & Biotech
ASX Health Stocks: Anteris successfully implants aortic valve, MGC Pharma a step closer to FDA submission
Health & Biotech
ASX Health Stocks: Recce Pharma and Impedimed surge 15pc after positive announcements
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
News
Market Highlights: ASX set for a quietly sub-optimal open after tech took a breather in the US
Health & Biotech
ASX Health Stocks: Anteris’ 3D heart valve shows consistent results; as Nyrada announces a new lead drug
Health & Biotech
ASX Health Stocks: Paradigm Bio says drug effective in dogs, HeraMED signs deal in US
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
News
In Case You Missed It: Lithium, lithium, some cannabis … and more lithium
Health & Biotech
ASX Health Stocks: Imugene’s liver cancer platform presented at prestigious conference
News
ASX Small Caps Lunch Wrap: Who else is crying out for some decent proofreaders this week?
Experts
CRITERION: The ASX cancer fighters with a sting in their treatment tails
News
Market Highlights: Tesla’s margins collapse, big announcement on RBA today, and 5 ASX small caps to watch
Health & Biotech
